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Introduction: Several cellular sources of stem cells have been tested in the attempt to yield innovative interventions
in acute kidney injury (AKI). Human liver stem cells (HLSCs) are cells isolated from the normal adult human liver
which are gaining attention for their therapeutic potential. In the present study, we investigated whether HLSCs
and the derived extracellular vesicles may promote tubular regeneration after AKI induced by glycerol injection in
severe-combined immune-deficient mice.
Methods: HLSCs were expanded and conditioned medium (CM) and extracellular vesicles (EVs) were purified. HLSCs
and their bioproducts were tested in a model of AKI induced by intra-muscle glycerol injection. Renal function and
morphology were evaluated five days after induction of damage. The effect of EVs on proliferation and apoptosis of
murine renal tubular cells was tested in vitro.
Results: We found that intravenous injection of 3.5×105 HLSCs into mice three days after induction of AKI significantly
improved functional and morphological recovery. The injection of HLSCs decreased creatinine and urea, as well as
hyaline cast formation, tubular necrosis and enhanced in vivo tubular cell proliferation. The effect of soluble factors
release by HLSCs in the regenerative processes was also studied. CM produced by HLSCs, mimicked the effect of the
cells. However, depletion of EVs significantly reduced the functional and morphological recovery of CM. Moreover, we
found that purified HLSC-derived EVs ameliorated renal function and morphology in a manner comparable to the cells.
In vitro HLSC-derived EVs were shown to stimulate proliferation and inhibit apoptosis of murine renal tubular cells.
Conclusions: These results indicate that HLSCs increase recovery after AKI. EVs are the main component of
HLSC-derived CM capable of promoting regeneration in experimental AKI.Introduction
We recently identified and characterized adult human
liver stem cells (HLSCs) [1]. HLSCs expressed markers
characteristic of the mesenchymal lineage together with
albumin and alpha-fetoprotein, suggesting a partial
hepatic commitment but lack of hematopoietic stem
markers. HLSCs were also able to undergo multiple
in vitro differentiations. In vivo, we demonstrated the
therapeutic potential of HLSCs in several experimental
models of liver injury [1,2]. We found that HLSCs
contribute to regeneration of the liver parenchyma in* Correspondence: giovanni.camussi@unito.it
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article, unless otherwise stated.acetaminophen induced-injury [1] and significantly attenu-
ate mouse mortality in a model of fulminant liver failure
in severe-combined immune-deficient (SCID) mice [2]. It
has been recently suggested that the biological effects of
stem cells are mediated by paracrine factors acting on
neighboring cells [3,4]. Indeed, Bi et al. showed that
conditioned medium (CM) derived from mesenchymal
stem cells (MSCs) diminishes the apoptosis of tubular
cells and limits renal injury [5] in a model of acute kidney
injury (AKI) induced by cisplatin. Similarly, in a model of
fulminant hepatic injury induced by D-galactosamine
and lipopolysaccharide, we found that CM from HLSCs
mimicked the beneficial effect of cells [2]. In addition
to soluble factors, extracellular vesicles (EVs) releasedd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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recovery after AKI [6,7].
A seminal work of De Broe et al. [8] demonstrated that
cell-derived circular plasma-membrane fragments retained
an enzymatic activity similar to that of the originating
cells. Subsequent studies demonstrated that EVs play a
critical role as mediators of cell-to-cell communication
[9]. Bruno et al. [6] showed that EVs released from MSCs
promoted the recovery from AKI, stimulated a prolifera-
tive program in tubular epithelial cells and reduced lethal-
ity in SCID mice treated with cisplatin [10]. Similarly,
EVs-derived from MSCs reduced injury and stimulated
recovery in a model of renal ischemia/reperfusion [7].
We found that, HLSC-derived EVs induced in vitro
proliferation and apoptosis resistance of human and rat
hepatocytes and accelerated in vivo the morphological
and functional recovery of the liver in a model of 70%
hepatectomy in rats [11].
The therapeutic potential of HLSCs in diseased organs
different from the liver has not yet been evaluated. The
aim of the present study was to investigate whether
HLSCs, HLSC-derived CM and HLSC-derived EVs con-
tribute to tubular regeneration in AKI induced in mice
by intramuscular injection of glycerol in SCID.
Methods
Isolation and characterization of HLSCs
HLSCs were isolated from human cryopreserved normal
adult hepatocytes (Lonza, Basel, Switzerland). The isolation,
culture and characterization of HLSCs were performed as
previously described [1]. Briefly, hepatocytes were initially
cultured for two weeks in Hepatozyme-SFM medium.
After the two weeks, most hepatocytes died, and then
the medium was substituted by α-MEM/EBM-1 (3:1)
(Invitrogen, Carlsbad, CA, USA) media supplemented
with l-glutamine (5 mM), Hepes (12 mM, pH 7.4),
penicillin (50 IU/ml), streptomycin (50 μg/ml) (all from
Sigma, St. Louis, MO, USA) and fetal calf serum (FCS)
(10%) (Invitrogen). Cells were expanded and characterized.
HLSCs expressed the mesenchymal stem cell markers
but not the hematopoietic and endothelial markers as
described [1]. HLSCs were also positive for human albu-
min and alpha-fetoprotein and for the resident stem cells
markers vimentin and nestin, and were negative for CD34,
CD117 and cytokeratin 19 oval cell markers [1]. HLSCs
also expressed the embryonic stem cell markers nanog,
Oct4, Sox2 and SSEA4 [2]. HLSCs were shown to undergo
osteogenic, endothelial and hepatic differentiation under
appropriate culture conditions [1].
Isolation of HLSC-derived EVs
EVs were obtained from supernatants of HLSCs (2 × 106
cells/T75) cultured for 24 hours in Roswell Park Memorial
Institute medium (RPΜΙ) deprived of FCS. The viability ofHLSCs at the time of EV collection was 97% to 99% as
detected by trypan blue exclusion and no apoptotic
cells were detectable by TUNEL assay.
After removal of cell debris and apoptotic bodies by
two centrifugations at 3,000 g for 20 minutes, EVs were
purified by two hours ultracentrifugation (100,000 g) at
4°C (Beckman Coulter Optima L-90 K, Fullerton, CA,
USA). EVs were used fresh or stored at −80°C after re-
suspension in RPMI supplemented with 5% dimethyl
sulfoxide (DMSO). No difference in biological activity
was observed between fresh and stored EVs.
To trace EVs by fluorescent microscopy, EVs were labeled
with 1 μM Dil dye (Molecular Probes, Life Technology, NY,
NY, USA) during ultracentrifugation [12]. After labeling,
EVs were washed by ultracentrifugation at 100,000 g for
one hour at 4°C. EV pellets were suspended in (D)MEM.
As control, EVs were inactivated by sonication (15 minutes
at 60 kHz) and heating (40°C) to disrupt the membrane
(iEV).
Analysis of the size distribution of EVs was performed
using NanoSight LM10 (NanoSight Ltd, Minton Park,
UK) [10].
Characterization of HLSC-derived EVs
EVs were characterized by cytofluorimetric analysis using
fluorescein isothiocyanate (FITC), phycoerythrin (PE) or
allophycocyanin (APC) conjugated antibodies against
CD73, CD44, CD105, CD90, CD107, CD63, CD29, CD81,
CD146 and HLA-class I. Conjugated mouse non-immune
isotypic immunoglobulin G (IgG) (Miltenyi Biotec,
Bergisch Gladbach, Germany) was used as control. Briefly,
EVs (0.15 × 109 particles) were incubated for 15 minutes at
4°C with antibodies, then diluted 1 to 3 and immediately
acquired as previously described [12,13]. Samples were ac-
quired using Guava easyCyte Flow Cytometer (Millipore,
Billerica, MA, USA) and analyzed with InCyte software.
We also performed fluorescence-activated cell sorting
(FACS) analysis after absorption on beads. Briefly, EVs (10
μg) were incubated for 30 minutes to overnight in ice with
5 μl of latex beads (Aldeyde/sulphate LATEX 4MM, Invi-
trogen), then washed in PBS supplemented with 100 mM
glycine and incubated for 30 minutes with the antibodies
described above.
Protein content of the EV preparations was quantified
by the Bradford method (Bio-Rad, Hercules, CA, USA).
Protein samples were separated by 4% to 15% gradient
sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis and subjected to immunoblotting with antibodies
CD63, CD81, Alix (Santa Cruz Biotechnology, Santa
Cruz CA, USA) and Hsp90 (Cell Signaling Technologies,
Danvers, MA, USA). The protein bands were visualized
with an enhanced chemiluminescence (ECL) detection
kit and ChemiDoc™ XRS + System (BioRad). Cell and EV
lysates were loaded at a concentration of 10 μg/well.
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HLSC-derived CM was produced as previously described
[2]. Briefly, HLSC-CM was obtained from 20 × 105 cells/
T75 cultured for 24 hours in RPΜΙ deprived of FCS as
for the collection of EVs. After two centrifugations at
3,000 g for 20 minutes to remove cell debris, cell-free
CM were concentrated 25-fold by centrifugation at
2,700 g for 75 minutes, using Ultra-PL 3 ultrafiltration
units (Amicon-Ultra; Millipore) with a 3-kDa molecular
weight cutoff. A total of 250 μL of CM was obtained.
To evaluate the contribution of EVs in the biological
effect of CM, in select experiments CM was depleted of
EVs by ultracentrifugation (100,000 g for five hours);
depletion was verified by NanoSight analyses, as described
below.
Isolation and culture of murine tubular epithelial cells
and in vitro experiments
Kidneys were obtained from healthy female C57 mice.
Murine tubular epithelial cells (mTEC) were isolated,
cultured and characterized for the presence of tubular
markers and for the absence of endothelial and glomeru-
lar markers as previously described by Bruno et al. [6].
To determine the incorporation efficacy of HLSC-
derived EVs, we incubated Dil labeled EVs, purified fromFigure 1 Effects of intravenous injection of HLSCs in AKI mice. (A) and
glycerol administration in mice injected with vehicle alone, with HLSCs (0.7
as mean ± SD; ANOVA with Dunnet’s multicomparison test: *P <0.05 HLSC-
(C) Effect of HLSCs injection on renal morphology at day 5 after AKI induct
high power (original magnification: ×400) is expressed as mean ± SD. ANO
3.5 × 105) AKI mice versus vehicle-treated AKI mice. (D) Representative microg
treated with vehicle alone or with different quantities of HLSCs (0.75 × 105; 3.5
aspect of hyaline cast formations and tubular necrosis are, respectively, shown
of variance; HLSCs, human liver stem cells; SD, standard deviation.25,000 HLSCs, with 25,000 mTEC for five hours. The
up-take of EVs was analyzed using confocal microscopy
(Zeiss LSM 5 Pascal, Carl Zeiss, Oberkochen, Germany).
For proliferation experiments, mTECs were seeded at
4,000 cells/well into 96-well plates in 100 μl/well of (D)
MEM low glucose with 2% FCS and in the presence of
CM deprived of EVs, EVs and iEV derived from 8,000
HLSCs. DNA synthesis was detected as incorporation
of 5-bromo-2′-deoxy-uridine (BrdU) into the cellular
DNA after 48 hours of culture (Roche Applied Science,
Mannheim, Germany).
For apoptosis experiments, mTECs were seeded at
25,000 cells/well into 24-well plates in (D)MEM low
glucose without FCS in the presence of CM deprived of
EVs, EVs and iEV derived from 50,000 HLSCs.
Cell death analysis was performed using the Muse_An-
nexin V & Dead Cell Assay (Millipore) after 48 hours. The
assay was performed according to the manufacturer’s
protocols.
SCID mice model of AKI
Animal studies were conducted in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals. The protocol entitled: ‘Experimen-
tal models of renal regenerative therapies’ was approved(B) Creatinine and blood urea nitrogen (BUN) values on day 5 after
5 × 105; 3.5 × 105) and in healthy (ctrl) SCID mice. Data are expressed
treated (0.75 × 105; 3.5 × 105) AKI mice versus vehicle-treated AKI mice.
ion. The number of hyaline casts and tubular necrosis observed under
VA with Dunnet’s multicomparison test: *P <0.05 HLSC-treated (0.75 × 105;
raphs of renal histology of healthy SCID mice (ctrl) and of AKI mice
× 105) and sacrificed at day 5. Original magnification: ×200. The typical
by asterisks and head arrows. AKI, acute kidney injury; ANOVA, analysis
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the University of Torino, Italy.
To evaluate the ability of HLSCs, HLSC-derived EVs
or HLSC-derived CM to improve kidney injury, we in-
duced AKI by intra-muscle injection of glycerol (Sigma)
in SCID mice as previously described [6]. Mice were
anesthetized with isoflurane and then injected with 50%
glycerol in water, 8 ml/kg, half of the dose injected into
each muscle of the inferior hind limbs. Glycerol in-
duced myolysis and hemolysis, thereby exposing the
kidney to large amounts of myoglobin and hemoglobin
[6]. The peak of tubular injury was observed three days
after glycerol injection. At this time, mice received differ-
ent treatments. The following groups were studied: group
1, AKI mice intravenously (iv) injected with vehicle alone
(n = 18); group 2, healthy mice iv injected with vehicle
alone (n = 6); group 3, AKI mice iv injected with 0.75 × 105
(n = 4) or 3.5 × 105 (n = 7) HLSCs; group 4, AKI mice ivFigure 2 Renal cell proliferation in AKI mice treated with HLSCs. Quantifi
sections of AKI mice treated with vehicle alone or with different quantities of H
two consecutive days before mice were killed. Data are expressed as mean ± S
HLSC-treated AKI mice versus vehicle-treated AKI mice. Representative microgr
kidneys five days after glycerol treatment (two days after vehicle or HLSC inject
of variance; BrdU, 5-bromo-2′-deoxy-uridine; HLSCs, human liver stem cells; PCNinjected with concentrated CM HLSC-derived non EV
depleted obtained from 3.5 × 105 HLSCs (n = 9), 10 × 105
HLSCs (n = 5), or 20 × 105 HLSCs (n = 10); group 5, AKI
mice iv injected with CM HLSC-derived EV depleted
(n = 11) obtained from 20 × 105 HLSCs; group 6, AKI
mice iv injected with EVs produced by 3.5 × 105 HLSCs
(n = 9; EV1) or with EVs derived from 10 × 105 HLSCs
(n = 4; EV2). Sonicated EVs produced by 3.5 × 105
HLSCs were iv injected in AKI mice (group 7, n = 3).
Finally, Dil labeled EV1 were injected in AKI (group 8,
n = 3) and in healthy mice (group 9, n = 3).
The iv injections were performed in 120 μL in the tail
vein. In all experiments, cells cultured in T75 flasks until
the 2 to 6 passage were detached by trypsin (0.5% w/v),
washed, and resuspended in PBS.
To quantify proliferation of renal cells, BrdU (100 mg/Kg)
was injected intraperitoneally for two consecutive days
before the mice were killed.cation of BrdU (A) and PCNA (B) positive cells/hpf was performed in renal
LSCs and sacrificed after five days. BrdU was injected intraperitoneally for
D. ANOVA with Dunnet’s multicomparison test was performed: * P <0.05
aphs of PCNA (C) or BrdU (D) uptake staining performed on sections of
ion). Original magnification: ×400. AKI, acute kidney injury; ANOVA, analysis
A, proliferating cell nuclear antigen; SD, standard deviation.
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Blood samples for measurement of blood urea nitrogen
(BUN) and plasma creatinine were collected five days after
glycerol-induced AKI. Plasma creatinine was measured
using a colorimetric microplate assay based on the Jaffe
reaction (Quantichrom Creatinine Assay, BioAssay Systems,
Hayward, CA, USA). BUN was measured by direct quanti-
fication of plasma urea with a colorimetric assay kit
according to the manufacturer’s protocol (Quantichrom
Urea Assay, BioAssay Systems).
Morphological studies
For renal histology, 5 μm-thick paraffin kidney sections
were routinely stained with hematoxylin and eosin (H&E,
Merck, Darmstadt, Germany) for microscopic examination.
Luminal hyaline casts and cell necrosis (denudation
of tubular basement membrane) were assessed in non-
overlapping fields (10 for each section) using a 40×
objective (high power field, HPF). The number of casts
and tubular profiles showing necrosis were recorded in
a single-blind fashion.
Immunohistochemistry for detection of proliferation of
tubular cells was performed as described previously [6].
Kidney sections were subjected to antigen retrieval, and
slides were blocked and labeled with 1:25 dilution of mono-
clonal anti BrdU antibody (Dako Cytomation, Milan, Italy),
or 1:400 of monoclonal anti-proliferating cell nuclearFigure 3 Effects of intravenous injection of HLSC-derived CM into AK
with vehicle alone and in HLSC-derived CM-treated mice five days after gly
mean ± SD; ANOVA with Dunnet’s multicomparison test: *P <0.05 HLSC-deriv
of HLSC-derived CM injections on tubular morphology at day 5 after AKI indu
tubules observed under high power (original magnification: ×400). ANOVA w
AKI mice versus vehicle-treated AKI mice. (D) Representative micrographs of r
alone or injected intravenously with concentrated CM derived from different
magnification: ×200). AKI, acute kidney injury; ANOVA, analysis of variance; BU
stem cells; SCID, severe–combined immune-deficient; SD, standard deviation.antigen (PCNA, Santa Cruz Biotechnology). Immuno-
peroxidase staining was performed using 1:300 dilution of
anti-mouse horseradish peroxidase (HRP, Pierce, Rockford,
IL, USA). Scoring for BrdU- and PCNA-positive cells was
carried out by counting the number of positive nuclei per
HPF (40×) in 10 randomly chosen sections of kidney cortex.
Confocal microscopy analysis was performed on frozen
sections for localization of Dil-labeled EVs in kidneys of
healthy and AKI mice. Sections were blocked and labeled
with rabbit anti laminin (Sigma) (1:100 dilution). Omission
of the primary antibodies or substitution with non immune
rabbit IgG was used as control. Alexa Fluor 488 anti-rabbit
(Molecular Probes) was used as secondary antibody.
Statistical analysis
Results are expressed as mean ± standard deviation (SD).
Statistical analysis was performed by using the t test,
analysis of variance (ANOVA) with Newmann-Keuls or
ANOVA with Dunnet’s multicomparison tests when
appropriate. A P value of <0.05 was considered significant.
Results
HLSCs favor AKI recovery
To determine whether HLSCs were capable of favoring
renal regeneration, we induced AKI in SCID mice with
an intramuscular injection of hypertonic glycerol. At day
3 after injury, 0.75 × 105 and 3.5 × 105 HLSCs wereI mice. Creatinine (A) and BUN (B) were measured in mice treated
cerol injection and in healthy control (ctrl) mice. Data are expressed as
ed CM-treated AKI mice versus vehicle-treated AKI mice. (C) Comparison
ction. Data are expressed as mean ± SD of hyaline cast and necrotic
ith Dunnet’s multicomparison test: *P <0.05 HLSC-derived CM-treated
enal histology of healthy SCID mice and of AKI mice treated with vehicle
quantities of HLSCs (CM (3.5 × 105), CM (10 × 105), CM (20 × 105)) (original
N, blood urea nitrogen; CM, conditioned medium; HLSCs, human liver
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AKI mice significant increases in plasma levels of
creatinine and BUN were observed at day 3 (Figure 1A
and B). Mice injected with 0.75 × 105 and 3.5 × 105 HLSCs
exhibited, at day 5 (48 hours after treatment), a significant
reduction of creatinine levels (Figure 1A and B) at both
cells concentrations, whereas a significant reduction of
BUN was observed only with 3.5 × 105 HLSCs (Figure 1A
and B). Histological analysis confirmed the functional
results (Figure 1C and D). The morphological alterations
observed in SCID mice with AKI included tubular hyaline
cast formation and tubular necrosis (Figure 1D). AKI mice
treated with 0.75 × 105 and 3.5 × 105 HLSCs had a signifi-
cantly lower number of hyaline cast formations and lower
number of necrotic tubules compared with AKI mice
treated with vehicle alone (Figure 1C and D).
The effect of HLSC treatment on tubular cell prolifer-
ation was investigated by studying the expression of
PCNA and the uptake of BrdU by tubular cells in treated
or untreated AKI mice (Figure 2). Proliferation of tubu-
lar cells was significantly increased in mice treated with
3.5 × 105 HLSCs with respect to AKI mice treated with
vehicle alone (Figure 2). The lower dose of HLSCs
(0.75 × 105) failed to stimulate tubular proliferation.Figure 4 Effect of concentrated CM depleted of EVs on AKI recovery.
vehicle alone or with CM depleted (AKI + CM w/o EVs) or not of EVs (AKI +
mean ± SD; Analysis of variance with Newmann-Keuls multicomparison tes
AKI mice; #P <0.05 CM + EVs- treated AKI mice versus CM w/o EVs-treated A
with HLSC-CM depleted or not of EVs. Data are expressed as mean ± SD of
magnification: ×400). Analysis of variance with Newmann-Keuls multicomp
mice, #P <0.05 CM + EV-treated AKI mice versus CM w/o EV-treated AKI mice.
treated with vehicle alone or CM with or without (w/o) EVs and CM+ EVs and
successive days before mice were killed. Data are expressed as mean ± SD. AN
CM+ EV-treated AKI mice versus vehicle-treated AKI mice. AKI, acute kidney in
blood urea nitrogen; CM, conditioned medium; EV, extracellular vesicles; HLSC
nuclear antigen; SD, standard deviation; w/o, without.CM reproduced the protective effect of HLSCs
In order to study the effect of paracrine factors pro-
duced by HLSCs, different preparations of concentrated
CM derived from 3.5 × 105, 10 × 105 and 20 × 105 HLSCs
were injected in AKI mice (Figure 3). At day 5 after
glycerol injection, treatments with CM resulted in
significant decreases of creatinine and BUN levels
(Figure 3A and B) compared to mice treated with
vehicle alone. Also, tubular injury improved in mice
treated with CM (Figure 3C and D). In particular,
hyaline tubular casts and the degree of necrosis were
reduced with respect to mice given vehicle alone. CM
produced by 3.5 × 105 HLSCs failed to attenuate tubu-
lar injury (Figure 3C and D).
Concentrated CM contained 71.0 ± 7.0 × 109 EVs/ml
as detected by Nanosight. In order to study the contri-
bution of EVs in the regenerative properties of CM,
EV-depleted CM obtained from 20 × 105 cells was used.
Depletion of EVs did not abrogate but significantly
reduced the functional and morphological recovery
(Figure 4A-C). More evident was the effect on prolifer-
ation. Only EV-containing CM was able to stimulate
proliferation as detected by PCNA expression and BrdU
incorporation (Figure 4D and E).Creatinine (A) and BUN (B) were measured in AKI mice treated with
CM + EVs) five days after glycerol injection. Data are expressed as
t was performed; *P <0.05 CM-treated AKI mice versus vehicle-treated
KI mice. (C) Comparison of tubular morphology in AKI mice injected
hyaline cast and tubular necrosis observed under high power (original
arison test *P <0.05 CM = treated AKI mice versus vehicle-treated AKI
Quantification of PCNA (D) and BrdU (E) positive cells/hpf in AKI mice
sacrificed after five days. BrdU was injected intraperitoneally for two
OVA with Dunnet’s multicomparison test was performed: * P <0.05
jury; ANOVA, analysis of variance; BrdU, 5-bromo-2′-deoxy-uridine; BUN,
s, human liver stem cells; hpf, high power field; PCNA, proliferating cell
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By nanoparticle tracking analysis (NTA) the EV popula-
tion appeared heterogeneous in size distribution (Figure 5).
The mean size of EVs was 174 ± 64 nm, with the presence
of small EVs with a diameter of about 60 nm (Figure 5A).Figure 5 Characterization of HLSC-derived EVs surface markers and N
1 shows the relationship between particle distribution (left Y axis) and part
percentage distribution of particles (percentile in right Y axis) and particle size
Nanoparticle Tracking Analysis (NTA). (B) Representative Western blot analysis
and derived EV (10 μg protein/well). (C-D) Representative FACS analyses of th
HLSC-derived EVs. Dot lines indicate the isotopic controls. Three different EV p
FACS, fluorescence-activated cell sorting; HLSC, human liver stem cell.The expression of some classical exosomal markers
(CD81, CD63, Alix and Hsp90) was detected by Western
blot analysis (Figure 5B).
Guava FACS analyses showed the presence of several
mesenchymal surface markers characteristic of HLSCs,TA analyses. (A) Nanosizer analysis of purified HLSC-derived EVs: curve
icle size (X axis); curve 2 shows the correlation between cumulative
(X axis). Mean size and particle concentration values were calculated by
of exosomal markers CD63, CD81, Alix and Hsp90 expressed by HLSCs
e expression of classical mesenchymal (C) and exosomal markers (D) by
reparations were tested with similar results. EVs, extracellular vesicles;
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markers CD81 and CD107 (Figure 5C and D). Similar
results were obtained by FACS analyses performed on
vesicles pre-absorbed on beads (not shown).
To evaluate the ability of EV-HLSCs to be incorporated
by mTEC, Dil labeled EVs were incubated with the cells.Figure 6 Up-take of EVs by murine tubular epithelial cells. (A) Represe
stained with Dil (red) by mTEC after five hours of incubation. Original magn
were performed with similar results. (B) Quantification of proliferation rate by
vehicle, EV, CM and iEV derived from 8,000 HLSCs. Experiments were conduct
multicomparison test was performed: *P <0.05 EV versus vehicle. (C) Evaluation
iEV derived from 50,000 HLSCs by Muse Annexin V & Dead Cell Assay. Data are
test was performed: *P <0.05 EV and CM versus vehicle; #P <0.05 CM versu
CM, conditioned medium; EV, extracellular vesicles; HLSCs, human liver ste
epithelial cells; SD, standard deviation.EV-HLSCs were incorporated by mTEC, as observed by
confocal microscopy after five hours of incubation at 37°C
(Figure 6A).
To understand the possible different effect of CM and
EVs derived from HLSCs on cell proliferation and apop-
tosis, in vitro experiments were performed. Incubation ofntative micrograph of incorporation of EVs collected from HLSCs
ification: ×630. Nuclei were stained with Hoechst. Three experiments
BrdU incorporation assay. mTEC (4,000 cells/well) were treated with
ed in triplicate. Data are expressed as mean ± SD; ANOVA with Dunnet’s
of apoptosis of mTEC (25,000 cells/well) treated with vehicle, CM, EV and
expressed as mean ± SD; ANOVA with Newmann-Keuls multicomparison
s EV. ANOVA, analysis of variance; BrdU, 5-bromo-2′-deoxy-uridine;
m cells; iEV, inactivated extracellular vesicles; mTEC, murine tubular
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with respect to control cells incubated with vehicle alone
or with CM deprived of EVs or with iEVs (Figure 6B).
Moreover, incubation of mTECs with CM completely
inhibited apoptosis induced by serum deprivation
(Figure 6C), indicating the relevant anti-apoptotic
effect of paracrine factors present in CM. EVs also
significantly reduced the apoptosis in mTEC but were
less effective than CM (Figure 6C).
No stimulation of proliferation and protection from
apoptosis was observed with iEVs.Figure 7 Effects of intravenous injection of purified EVs released from
mice (A) and of AKI mice (B) treated with Dil labeled EVs (red), five hours a
blue with Hoechst and laminin in green. (C) Creatinine and (D) BUN values o
ANOVA with Dunnet’s multicomparison test was performed: *P <0.05 EV-
micrographs of renal histology of control healthy mice (ctrl) or AKI mice
alone (AKI + vehicle) or with EVs derived from 3.5 × 105 HLSCs (EV1) or from 1
HLSC-derived EV injection on tubular morphology at day 5 after AKI induction
observed under high power (original magnification: ×400). ANOVA with Dunn
versus vehicle-treated AKI mice. (G) Quantification of PCNA-positive cells/hpf
of AKI. Data are expressed as mean ± SD; ANOVA with Dunnet’s multicompar
AKI, acute kidney injury; ANOVA, analysis of variance; BUN, blood urea nitroge
stem cells; hpf, high power field; PCNA, proliferating cell nuclear antigen; SD,HLSC-derived EVs mediated the improvement of renal
function and morphology in AKI and stimulated tubular
cell proliferation
Labeled EVs, produced by 3.5 × 105 HLSCs (EV1), were
injected in healthy and AKI mice; five hours after the
injection mice were sacrificed and kidneys recovered for
analysis. Labeled EVs accumulated preferentially within
injured kidneys (Figure 7A and B) and were detectable
within tubules and glomeruli. Two concentrations of
purified EVs (EV1 = 1.88 ± 0.6 × 109 particles produced
by 3.5 × 105 HLSCs; EV2 = 5.53 ± 2.15 × 109 particles pro-HLSCs. (A-B) Representative micrographs of renal tissues of healthy
fter the injection. Original magnification: ×630. Nuclei were stained in
n day 5 after glycerol administration. Data are expressed as mean ± SD;
treated AKI mice versus vehicle-treated AKI mice. (E) Representative
at day 5 after glycerol administration intravenously injected with vehicle
0 × 105 HLSCs (EV2). Original magnification: ×400. (F) Comparison of
. Data are expressed as mean ± SD of hyaline casts and necrotic tubules
et’s multicomparison test was performed: *P <0.05 EV-treated AKI mice
in AKI mice untreated or treated with HLSC-derived EVs after five days
ison test: *P <0.05 EV- treated AKI mice versus vehicle- treated AKI mice.
n; CM, conditioned medium; EV, extracellular vesicles; HLSCs, human liver
standard deviation.
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induction of AKI. At day 5 after glycerol injection, EVs
significantly decreased creatinine and BUN plasma levels
(Figure 7C and D) and improved tubular injury (Figure 7E
and F) when compared with vehicle alone. The increased
expression of PCNA by tubular cells suggested that EVs
stimulated proliferation (Figure 7G).
The injection of iEV did not accelerate the recovery of
the tubular damage (Figure 7C and D).Discussion
In the present study, we demonstrated that HLSCs favor
recovery of glycerol-induced AKI in SCID mice. More-
over, CM of HLSCs mimicked the effect of the cells. EV
depletion significantly reduced the healing properties of
CM. Purified EVs had the same effect as HLSCs sug-
gesting that HLSC-derived EVs are responsible for the
improved renal function.
Several studies demonstrated the beneficial effect of
stem cells in the murine experimental model of AKI
[14-16]. Many studies focused on the exogenous
administration of MSCs because of their regenerative
potential and tropism for damaged tissues [15,17]. The
infusion of murine MSCs has been shown to accelerate
kidney recovery in cisplatin- or glycerol-induced AKI
[14,15]. In ischemia-reperfusion injury, rat MSCs pro-
tected from ischemic acute renal failure through the
production of factors with anti-apoptotic and mitogenic
activity [18]. The low number of MSCs engrafted in the
injured kidney in the face of the strong functional
recovery raised the hypothesis that soluble mediators
may explain the renoprotective effect of MSCs [19]. It
has been suggested that EVs may interact with target
cells and transfer functional proteins, micro-RNAs and
mRNAs that may modify their phenotype [9,20]. The
biological effect of human MSC-derived EVs has been
shown in several xenogenic models suggesting that
carried biological molecules are also active in different
species [6,7,21-24].
In a recent study, Bruno et al. [6] documented that EVs
produced by MSCs shuttled a specific subset of cellular
mRNAs that stimulate survival and proliferation of injured
tubular cells. Furthermore, in a lethal model of AKI
induced by cisplatin, we found that EVs released by MSCs
enhanced survival and that multiple injections of EVs
restored normal histology and renal function at day 21 [10].
On the other hand, we found that HLSC paracrine me-
diators also exert biological activities [2,11]. We demon-
strated that HLSC-derived EVs stimulated proliferation and
favored regeneration in a model of 70% hepatectomy in rats
by a mechanism involving the transfer of specific mRNA
subsets [11]. Moreover, the injection of HLSC-derived CM
significantly attenuates mouse mortality in a model offulminant liver failure induced by D-galactosamine and
lipopolysaccharide in SCID mice [2].
In the present study, we found that iv injection of
HLSCs at a concentration of 3.5 × 105 cells/mouse in
SCID mice with glycerol-induced AKI protected mice
from tubular injury and functional impairment. HLSCs
promoted histological and functional amelioration of
renal damage; moreover, HLSCs stimulated proliferation
of tubular epithelial cells. When we injected CM derived
from HLSCs in injured SCID mice, we observed an
improvement of function and morphological recovery of
kidney in comparison with mice treated with vehicle
alone. However, when CM was depleted of EVs by
ultracentrifugation, CM failed to stimulate tubular prolif-
eration. In contrast, purified EVs reproduced the same
biological effect as HLSCs promoting AKI recovery. In
vitro HLSC-derived EVs stimulated proliferation and
inhibited apoptosis of murine renal tubular cells.
Conclusions
The results of the present study indicate that HLSCs
have a healing action in a model of AKI characterized by
extensive damage of proximal tubular epithelial cells. HLSC
treatment improved renal function and stimulated prolifer-
ation of tubular epithelial cells thus favoring recovery. CM
mimicked the effect of HLSCs suggesting a paracrine
mechanism involving EVs released by these cells. In fact,
CM depleted of EVs abated the beneficial effect and puri-
fied EVs exhibited the same regenerative effect as HLSCs.
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